CN108929313A - Piperazine -2,5- diketone of 3R- indole methyl -6R- fatty acid/amino acid modification, synthesis, activity and application - Google Patents

Piperazine -2,5- diketone of 3R- indole methyl -6R- fatty acid/amino acid modification, synthesis, activity and application Download PDF

Info

Publication number
CN108929313A
CN108929313A CN201710364632.XA CN201710364632A CN108929313A CN 108929313 A CN108929313 A CN 108929313A CN 201710364632 A CN201710364632 A CN 201710364632A CN 108929313 A CN108929313 A CN 108929313A
Authority
CN
China
Prior art keywords
amino
piperazine
methyl
boc
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710364632.XA
Other languages
Chinese (zh)
Other versions
CN108929313B (en
Inventor
赵明
彭师奇
王玉记
吴建辉
张筱宜
丛林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Medical University
Original Assignee
Capital Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Medical University filed Critical Capital Medical University
Priority to CN201710364632.XA priority Critical patent/CN108929313B/en
Publication of CN108929313A publication Critical patent/CN108929313A/en
Application granted granted Critical
Publication of CN108929313B publication Critical patent/CN108929313B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses (the 3R of following formula; 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine-2,5-dione (AA is L-Ala residue, Gly residue, L-Met residue and L-IIe residue in formula).It discloses their preparation method, disclose their anti-tumor activity, disclose their activity of resisting tumor metastasis, and their anti-inflammatory activity activity is disclosed, thus anti-tumor drug is being prepared the invention discloses them, the application in medicine for anti transfer of tumor and anti-inflammatory drug.

Description

Piperazine -2,5- diketone of 3R- indole methyl -6R- fatty acid/amino acid modification, synthesis, Activity and application
Technical field
The present invention relates to (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazines - 2,5- diketone.It is related to their preparation method, is related to their anti-tumor activity, is related to their activity of resisting tumor metastasis, with And be related to their anti-inflammatory activity activity, thus preparing anti-tumor drug the present invention relates to them, medicine for anti transfer of tumor and Application in anti-inflammatory drug.The invention belongs to biomedicine fields.
Background technique
Tumour seriously threatens the health of the mankind.Other than itself is severe to the prognosis of tumor patient, tumor complicated turns Move the prognosis for further deteriorating patient.For example, being all to die of transfer more than 90% or more tumor patient.Due to existing antineoplastic Object does not have inhibiting effect on tumor metastasis, so the clinical efficacy of chemotherapy of tumors is undesirable.The drug of invention anti-tumor metastasis is clinical Urgent need.Before this, inventor once discloses S, S-, R, R-, R, S- and S, and the diketopiperazine of tetra- kinds of configurations of R- is dense at 0.5 μM Degree can inhibit HCCLM3 (high-transfer human liver cancer cell) migration and invasion.Later inventor discloses R, the diketopiperazine of R- configuration again The tumour of C57BL/6 mouse be can inhibit under 5 μm of ol/kg dosage to Lung metastases.But minimum effective dose is 5 μm of ol/kg.For Reduction minimum effective dose, inventor expand various modifications to R, the fourth amino of the diketopiperazine of R- configuration.It was visited by 3 years Rope, the discovery acylated R of fatty acid/amino acid (L-Ala, Gly, L-Met and L-IIe) acylated aminocaproic acid, the diketone piperazine of R- configuration The n-butyl amine base of piperazine can not only make the minimum effective dose of anti-tumor metastasis be down to 0.5 μm of ol/kg, but also can make antitumor and anti- Scorching minimum effective dose is all down to 0.5 μm of ol/kg.It disappears because the toxic side effect of drug can be reduced with dosage, institute Showing this structural modification with 10 times of effective dose reduction has technical effect outstanding.According to these discoveries, inventor is proposed The present invention.
Summary of the invention
First content of the invention is to provide (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino)-of following formula (AA is that L-Ala residue, Gly residue, L-Met residue and L-IIe are residual to 6- (indoles -3- methyl)-piperazine-2,5-dione in formula Base).
Second content of the invention is to provide (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (Yin Diindyl -3- methyl)-piperazine-2,5-dione (in formula AA be L-Ala residue, Gly residue, L-Met residue and L-IIe residue) conjunction At method, this method includes：
(1) D-Boc-Lys (Cbz) and D-Trp-OBzl are condensed to obtain D-Boc-Lys (Cbz)-D-Trp-OBzl；
(2) D-Boc-Lys (Cbz)-D-Trp-OBzl de- Boc in the ethyl acetate solution of hydrogen chloride obtains D-Lys (Cbz)-D-Trp-OBzl；
(3) D-Lys (Cbz)-D-Trp-OBzl containing 5% sodium bicarbonate aqueous solution saturation ethyl acetate middle ring symphysis at (3R, 6R) -3- (benzyloxycarbonyl amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (1)；
(4) the de- benzyloxycarbonyl group of 1 hydrogenolysis of compound obtains (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine Piperazine -2,5- diketone (2)；
(5) Amino-n-hexanoic acid methyl esters and Boc-AA (AA is Ala residue, Gly residue, Met residue and IIe residue in formula) contracting Close to obtain R-AA- Amino-n-hexanoic acid methyl esters (3a-d)；
(6) compound 3a-c saponification removing methyl esters obtains Boc-AA- Amino-n-hexanoic acid (4a-d)；
(7) compound 2 and compound 4a-d are condensed (3R, 6R) -3- (positive positive fourth of caproyl amino of Boc-AA- amino Base) -6- (indoles -3- methyl)-piperazine-2,5-dione (5a-d)；
(8) compound 5a-d in the ethyl acetate solution of hydrogen chloride take off Boc obtain (3R, 6R) -3- (AA- amino just oneself Acyl amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (6a-d).
Third content of the invention is evaluation (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (Yin Diindyl -3- methyl)-piperazine-2,5-dione (AA is L-Ala residue, Gly residue, L-Met residue and L-IIe residue in formula) inhibition C57BL/6 mouse anti-lung cancer transfer activity.
4th content of the invention is evaluation (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (Yin Diindyl -3- methyl)-piperazine-2,5-dione (in formula AA be L-Ala residue, Gly residue, L-Met residue and L-IIe residue) is to ICR The inhibiting effect of mouse inflammation.
5th content of the invention is evaluation (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (Yin Diindyl -3- methyl)-piperazine-2,5-dione (in formula AA be L-Ala residue, Gly residue, L-Met residue and L-IIe residue) is right The inhibition application of S180 mice tumors grew.
Detailed description of the invention
Fig. 1 (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine -2,5- two AA is L-Ala residue in the synthetic route .3a-6a of ketone (6a-g)；AA is Gly residue in 3b-6b；AA is that L-Met is residual in 3c-6c Base；AA is L-Ile residue in 3d-6d；I) dicyclohexylcarbodiimide (DCC), I-hydroxybenzotriazole (HOBt), N- methyl Quinoline (NMM), tetrahydrofuran (THF)；Ii) the ethyl acetate solution of hydrogen chloride；Iii) ethyl acetate, 5% sodium bicarbonate；Iv) two Methylformamide (DMF), Pd/C, H2；V) dicyclohexylcarbodiimide (DCC), I-hydroxybenzotriazole (HOBt), N- methyl Quinoline (NMM), N,N-dimethylformamide (DMF)；Vi) methanol, NaOH (2M).
Specific embodiment
In order to which the present invention is further explained, a series of embodiments are given below.These embodiments be entirely it is illustrative, it Only be used to the present invention is specifically described, be not construed as limitation of the present invention.
Embodiment 1 prepares D-Boc-Lys (Cbz)-D-Trp-OBzl
7.7g (20mmol) D-Boc-Lys (Cbz) is suspended in 100mL anhydrous tetrahydro furan (THF), under ice bath according to It is secondary to add 2.7g (20mmol) 1- hydroxy benzo triazole (HOBt) and 5.0g (25mmol) dicyclohexyl carbon two sub- into suspension Amine (DCC), then stirs 30min.Later, add 8.0g (25mmol) D-Trp-OBzl.N- methyl is added dropwise in compound of reaction Morpholine (NMM) adjusts pH to 9.Reaction mixture first stirs 1h under ice bath, then 12h is stirred at room temperature.Compound of reaction filtering, filter Liquid is concentrated under reduced pressure, and residue 150mL ethyl acetate solution dissolves.Obtained ethyl acetate solution successively uses 5%KHSO4It is water-soluble Liquid is washed 3 times, and saturation NaCl aqueous solution is washed 3 times.Ethyl acetate layer anhydrous Na2SO4Dry 12h, filtering, filtrate decompression are concentrated into It is dry.Obtained yellow syrup object is purified by silica gel column chromatography (CH2Cl2/CH3OH,100:1) 12.0g (88%) title compound is obtained Object is colorless solid.ESI-MS(m/e):657[M+H]+。
Embodiment 2 prepares D-Lys (Cbz)-D-Trp-OBzl
The acetic acid of 3.8g (5mmol) D-Boc-Lys (Cbz)-D-Trp-OBzl and 52mL hydrogen chloride under ice bath and stirring Ethyl ester solution (4M) is slowly mixed together.Obtained solution stirs 5h in ice bath.Later, reaction mixture is concentrated under reduced pressure.Residue It is dissolved with 50mL anhydrous ethyl acetate, obtained solution is concentrated under reduced pressure.The operation is in triplicate.Residue anhydrous ether is abundant It washes, obtains 3.41g (93%) title compound, be yellow powder.ESI-MS(m/e):557[M+H]+。
Embodiment 3 prepares (3R, 6R) -3- (benzyloxycarbonyl amino normal-butyl) -6- (indoles -3- methyl)-piperazine -2,5- two Ketone (1)
3.45g (6.2mmol) D-Boc-Lys (Cbz)-D-Trp-OBzl 150mL ethyl acetate is dissolved.What is obtained is molten After liquid is washed three times with the sodium bicarbonate aqueous solution that concentration is 5%, 12h, which is stirred at room temperature, in ethyl acetate solution keeps colorless solid abundant It is precipitated.Filter out 1.8g (51%) title compound.ESI-MS(m/e):449[M+H]+。
Embodiment 4 prepares (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (2)
Past 1.9g (4.2mmol) (3R, 6R) -3- (benzyloxycarbonyl amino normal-butyl) -6- (indoles -3- methyl)-piperazine -2, In 5- diketone (1) and the solution of the anhydrous n,N-Dimethylformamide of 20mL (DMF) plus 200mgPd/C, room temperature lead to H248h.It filters off Pd/C, filtrate decompression are concentrated to give 1.2g (92%) title compound, are colourless powder.ESI-MS(m/e)：315[M+H]+.
Embodiment 5 prepares Amino-n-hexanoic acid methyl esters
Into 40mL methanol be added dropwise 5.6mL thionyl chloride, stir 30min after, be added 2.62g (20mmol) amino just oneself 12h is stirred at room temperature in acid.Dry methanol is added in reaction solution decompressing and extracting with water pump under 37 DEG C of tepidarium stirrings of compound of reaction Water pump decompressing and extracting is used after dissolution, is repeated 3 times；Anhydrous ether is added to be suspended, lower decompressing and extracting is stirred in 37 DEG C of tepidariums, repeats 3 It is secondary, obtain 2.72g (95%) title compound.ESI-MS(m/e):145[M+H]+
Embodiment 6 prepares Boc-Ala- Amino-n-hexanoic acid methyl esters (3a)
Using the method for embodiment 1 from 945mg (5.0mmol) Boc-Ala and 720mg (5.0mmol) Amino-n-hexanoic acid first Ester obtains 1480mg (94%) title compound, is colorless solid.ESI-MS(m/e):317[M+H]+。
Embodiment 7 prepares Boc-Gly- Amino-n-hexanoic acid methyl esters (3b)
Using the method for embodiment 1 from 880mg (5.0mmol) Boc-Gly and 720mg (5.0mmol) Amino-n-hexanoic acid first Ester obtains 1390mg (92%) title compound, is colorless solid.ESI-MS(m/e):303[M+H]+。
Embodiment 8 prepares Boc-Met- Amino-n-hexanoic acid methyl esters (3c)
Using the method for embodiment 1 from 1245mg (5.0mmol) Boc-Met and 720mg (5.0mmol) Amino-n-hexanoic acid first Ester obtains 1540mg (82%) title compound, is colorless solid.ESI-MS(m/e):377[M+H]+。
Embodiment 9 prepares Boc-Ile- Amino-n-hexanoic acid methyl esters (3d)
Using the method for embodiment 1 from 1160mg (5.0mmol) Boc-Trp and 720mg (5.0mmol) Amino-n-hexanoic acid first Ester obtains 1580mg (89%) title compound, is colorless solid.ESI-MS(m/e):359[M+H]+。
Embodiment 10 prepares Boc-Ala- Amino-n-hexanoic acid (4a)
By 0.94g (3.0mmol) Boc-Ala- Amino-n-hexanoic acid methyl esters (3a) 20mL CH3OH dissolution.Obtained solution NaOH aqueous solution (2M) is added under ice bath stirring and adjusts pH value to 12, ice bath stirring reacts 6h.Reaction solution is used under ice bath stirring It is saturated KHSO4Solution adjusts pH value to 7, obtains solution reduced pressure.Residue 5%KHSO4Aqueous solution adjusts pH value to 2.? To solution be extracted with ethyl acetate 3 times, then by ethyl acetate solution with saturation NaCl aqueous solution be washed till neutrality.Ethyl acetate layer Use anhydrous Na2SO4Dry 12h, filtering, filtrate decompression are concentrated to dryness.1.12g title compound is obtained, is faint yellow syrup. ESI-MS(m/e):303[M+H]+。
Embodiment 11 prepares Boc-Gly- Amino-n-hexanoic acid (4b)
1.10g is obtained from 0.90g (3.0mmol) Boc-Gly- Amino-n-hexanoic acid methyl esters (3b) using the method for embodiment 10 Title compound is faint yellow syrup.ESI-MS(m/e):289[M+H]+。
The preparation preparation of embodiment 12 Boc-Met- Amino-n-hexanoic acid (4c)
1.50g is obtained from 1.12g (3.0mmol) Boc-Met- Amino-n-hexanoic acid methyl esters (3c) using the method for embodiment 10 Title compound is faint yellow syrup.ESI-MS(m/e):363[M+H]+。
The preparation preparation of embodiment 13 Boc-Ile- Amino-n-hexanoic acid (4d)
1.35g is obtained from 1.07g (3.0mmol) Boc-Ile- Amino-n-hexanoic acid methyl esters (3d) using the method for embodiment 10 Title compound is faint yellow syrup.ESI-MS(m/e):345[M+H]+。
Embodiment 14 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Boc-Ala- amino) -6- (indoles -3- first Base)-piperazine-2,5-dione (5a)
Using the method for embodiment 1 from the Boc-Ala- Amino-n-hexanoic acid (4a) and 940mg of the faint yellow syrup of 1120mg (3.0mmol) (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (2) obtains 780mg (44%) title compound is colorless solid.ESI-MS(m/e):599[M+H]+；1H NMR(500MHz,DMSO-d6):δ/ppm =10.896 (m, 1H), 8.975 (d, J=1.5Hz, 1H), 7.966 (d, J=1.5Hz, 1H), 7.741 (t, J=5.4Hz, 1H), 7.581 (m, 2H), 7.306 (m, 1H), 7.048 (m, 2H), 6.927 (t, J=7.2Hz, 2H), 6.820 (d, J= 7.5Hz,1H),4.130(m,1H),3.919(m,1H),3.515(m,1H),3.269(dd,J1=14.4Hz, J2=4.2Hz, 1H), 3.012 (m, 3H), 2.766 (m, 2H), 2.014 (t, J=7.2Hz, 2H), 1.420 (m, 2H), 1.367 (m, 11H), 1.255(m,6H),0.952(m,3H),0.585(m,3H)。
Embodiment 15 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Boc-Gly- amino) -6- (indoles -3- first Base)-piperazine-2,5-dione (5b)
Using the method for embodiment 1 from the Boc-Gly- Amino-n-hexanoic acid (4b) and 940mg of the faint yellow syrup of 1100mg (3.0mmol) (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (2) obtains 390mg (22%) title compound is colorless solid.ESI-MS(m/e):585[M+H]+；1H NMR(300MHz,DMSO-d6):δ/ppm =10.881 (s, 1H), 8.044 (d, J=1.8Hz, 1H), 7.937 (d, J=1.8Hz, 1H), 7.721 (t, J=5.1Hz, 1H), 7.576 (m, 2H), 7.298 (d, J=6.9Hz, 1H), 7.023 (m, 2H), 6.912 (m, 2H), 4.110 (m, 1H), 3.482(m,2H),3.345(m,1H),3.247(dd,J1=4.2Hz, J2=14.4Hz, 1H), 3.022 (m, 3H), 2.764 (m, 2H), 2.006 (t, J=7.2Hz, 2H), 1.436 (m, 12H), 1.224 (m, 2H), 0.964 (m, 3H), 0.554 (m, 3H).
Embodiment 16 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Boc-Met- amino) -6- (indoles -3- first Base)-piperazine-2,5-dione (5c)
Using the method for embodiment 1 from the Boc-Met- Amino-n-hexanoic acid (4c) and 940mg of the faint yellow syrup of 1500mg (3.0mmol) (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (2) obtains 310mg (16%) title compound is colorless solid.ESI-MS(m/e):659[M+H]+；1H NMR(300MHz,DMSO-d6):δ/ Ppm=10.886 (d, J=1.5Hz, 1H), 8.059 (d, J=2.1Hz, 1H), 7.949 (d, J=2.1Hz, 3H), 7.787 (t, J=5.4Hz, 1H), 7.575 (m, 2H), 7.298 (d, J=8.1Hz, 1H), 7.022 (m, 2H), 6.926 (m, 2H), 4.111 (m, 1H), 3.931 (m, 1H), 3.499 (m, 1H), 3.248 (dd, J1=14.4Hz, J2=4.2Hz, 1H), 2.989 (m, 3H), 2.734(m,2H),2.416(m,1H),2.002(m,5H),1.766(m,2H),1.145(m,13H),1.200(m,2H), 0.960(m,3H),0.552(m,3H)。
Embodiment 17 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Boc-Ile- amino) -6- (indoles -3- first Base)-piperazine-2,5-dione (5d)
Using the method for embodiment 1 from the Boc-Ile- Amino-n-hexanoic acid (4d) and 940mg of the faint yellow syrup of 1350mg (3.0mmol) (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (2) obtains 710mg (37%) title compound is colorless solid.ESI-MS(m/e):641[M+H]+；1H NMR(500MHz,DMSO-d6):δ/ppm =10.890 (s, 1H), 8.070 (d, J=1.5Hz, 1H), 7.956 (d, J=1.5Hz, 1H), 7.845 (t, J=5.1Hz, 1H), 7.586 (m, 2H), 7.295 (m, 1H), 7.031 (m, 2H), 6.923 (t, J=7.2Hz, 1H), 4.109 (m, 1H), 3.732 (t, J=8.4Hz, 2 H), 3.497 (m, 1H), 3.248 (dd, J1=14.1Hz, J2=3.9Hz, 1H), 3.033 (m, 3H), 2.743 (m, 2H), 1.997 (t, J=7.5Hz, 2H), 1.635 (m, 1H), 1.444 (m, 15H), 1.204 (m, 3H), 0.976(m,3H),0.800(m,6H),0.556(m,3H)。
Embodiment 18 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Ala- amino) -6- (indoles -3- methyl)-piperazine Piperazine -2,5- diketone (6a)
According to the method for embodiment 3 from 300mg (0.5mmol) (3R, 6R) -3- (positive caproyl amino of Boc-Ala- amino Normal-butyl) -6- (indoles -3- methyl)-piperazine -2,5- diketone (5a) obtains 230mg (92%) title compound, and it is colourless solid Body.ESI-MS(m/e):499[M+H]+；Mp 148-150℃；(C=0.1, H2O)；1H NMR(500MHz, DMSO-d6):δ/ppm=10.901 (d, J=1.5Hz, 1H), 8.250 (t, J=5.5Hz, 1H), 8.020 (d, J=2Hz, 1H), 7.922 (d, J=2Hz, 1H), 7.601 (t, J=5.5Hz, 1H), 7.569 (d, J=8Hz, 1H), 7.302 (d, J= 8Hz,2H),7.016(m,2H),6.915(m,1H),4.105(m,1H),3.637(m,1H),3.499(m,1H),3.236(dd, J1=14.5Hz, J2=4.5Hz, 1H), 3.059 (m, 3H), 2.757 (m, 2H), 2.016 (m, 2H), 1.440 (m, 4H), 1.255 (m,5H),0.974(m,3H),0.612(m,3H)。
Embodiment 19 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Gly- amino) -6- (indoles -3- methyl)-piperazine Piperazine -2,5- diketone (6b)
According to the method for embodiment 3 from 300mg (0.5mmol) (3R, 6R) -3- (positive caproyl amino of Boc-Gly- amino Normal-butyl) -6- (indoles -3- methyl)-piperazine -2,5- diketone (5b) obtains 220mg (90%) title compound, and it is colourless solid Body.ESI-MS(m/e):499[M+H]+；Mp 148–150℃；(C=0.1, H2O)；1H NMR(500MHz, DMSO-d6):δ/ppm=10.901 (d, J=1.5Hz, 1H), 8.250 (t, J=5.5Hz, 1H), 8.020 (d, J=2Hz, 1H), 7.922 (d, J=2Hz, 1H), 7.601 (t, J=5.5Hz, 1H), 7.569 (d, J=8Hz, 1H), 7.302 (d, J= 8Hz,2H),7.016(m,2H),6.915(m,1H),4.105(m,1H),3.637(m,1H),3.499(m,1H),3.236(dd, J1=14.5Hz, J2=4.5Hz, 1H), 3.059 (m, 3H), 2.757 (m, 2H), 2.016 (m, 2H), 1.440 (m, 4H), 1.255 (m,5H),0.974(m,3H),0.612(m,3H)。
Embodiment 20 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Met- amino) -6- (indoles -3- methyl)-piperazine Piperazine -2,5- diketone (6c)
According to the method for embodiment 3 from 300mg (0.4mmol) (3R, 6R) -3- (positive caproyl amino of Boc-Met- amino Normal-butyl) -6- (indoles -3- methyl)-piperazine -2,5- diketone (5c) obtains 120mg (47%) title compound, and it is colourless solid Body.ESI-MS(m/e):559[M+H]+；Mp 137–138℃；(C=0.1, H2O)；1H NMR(300MHz, DMSO-d6):δ/ppm=10.922 (s, 1H), 8.572 (s, 1H), 8.294 (s, 3H), 8.035 (s, 1H), 7.936 (s, 1H), 7.592 (m, 2H), 7.308 (d, J=8.7Hz, 1H), 7.028 (m, 2H), 6.931 (m, 1H), 4.115 (m, 1H), 3.808 (m, 1H),3.505(m,1H),3.147(m,4H),2.768(m,2H),2.019(m,5H),1.450(m,6H),1.258(m,3H), 1.063(m,3H),0.618(m,3H)。
Embodiment 21 prepares (3R, 6R) -3- (the positive caproyl amino normal-butyl of Ile- amino) -6- (indoles -3- methyl)-piperazine Piperazine -2,5- diketone (6d)
According to the method for embodiment 3 from 300mg (0.5mmol) (3R, 6R) -3- (positive caproyl amino of Boc-Ile- amino Normal-butyl) -6- (indoles -3- methyl)-piperazine -2,5- diketone (5d) obtains 230mg (92%) title compound, and it is colourless solid Body.ESI-MS(m/e):541[M+H]+；Mp 162–164℃；(C=0.1, H2O)；1H NMR(500MHz, DMSO-d6):δ/ppm=10.914 (d, J=1.5Hz, 1H), 8.416 (t, J=5.0Hz, 1H), 8.021 (d, J=2.0Hz, 1H), 7.923 (d, J=2.0Hz, 1H), 7.877 (m, 2H), 7.618 (t, J=5.5Hz, 1H), 7.569 (d, J=8.0Hz, 1H), 7.297 (d, J=8.0Hz, 1H), 7.035 (m, 2H), 6.921 (m, 1H), 4.103 (m, 1H), 3.506 (m, 2H), 3.234(dd,J1=14.5Hz, J2=4.0Hz, 1H), 3.181 (m, 1H), 3.024 (m, 2H), 2.757 (m, 2H), 2.019 (t, J=7.5Hz, 2H), 1.784 (m, 1H), 1.444 (m, 5H), 1.246 (m, 2H), 1.093 (m, 1H), 0.975 (m, 1H), 0.870(m,6H),0.593(m,3H)。
Embodiment 22 prepares (3R, 6R) -3- (Boc- aminocaProyl fourth amino) -6- (indoles -3- methyl)-piperazine -2, 5- diketone (7)
Using the method for embodiment 1 from 0.97g (4.2mmol) Boc- aminocaproic acid and 1.9g (3.5mmol) (3R, 6R)- 3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine -2,5- diketone (2) obtains 0.641g (21%) title compound, is Colorless solid.
ESI-MS(m/e):528[M+H]+；1H NMR(300MHz,DMSO-d6):δ/ppm=10.872 (s, 1H), 8.035 (d, J=1.8Hz, 1H), 7.928 (d, J=1.8Hz, 1H), 7.560 (m, 2H), 7.303 (d, J=5.7Hz, 1H), 7.034 (m, 2H), 6.925 (t, J=7.5Hz, 1H), 6.763 (t, J=5.1Hz, 1H), 4.108 (m, 1H), 3.499 (m, 1H), 3.246(dd,J1=14.4Hz, J2=4.2Hz, 1H), 3.009 (dd, J1=14.4Hz, J2=4.2Hz, 1H), 2.890 (q, J =6.6Hz, 2H), 2.750 (q, J=6.6Hz, 2H), 2.002 (t, J=7.2Hz, 2H), 1.465 (m, 2H), 1.350 (m, 12H),1.205(m,3H),0.951(m,3H),0.553(m,3H)。
Embodiment 23 prepares (3R, 6R) -3- (aminocaProyl fourth amino) -6- (indoles -3- methyl)-piperazine -2,5- two Ketone (8)
Using the method for embodiment 3 from 2.21g (4mmol) (3R, 6R) -3- (Boc- aminocaProyl fourth amino) -6- (Yin Diindyl -3- methyl)-piperazine -2,5- diketone (7) obtains 1.45g (82%) title compound, and it is colourless powder.ESI-MS(m/e): 428[M+H]+；1HNMR(300MHz,DMSO-d6):δ/ppm=11.003 (s, 1H), 8.086 (s, 1H), 7.999 (s, 1H), 7.748 (s, 1H), 7.578 (s, J=8.1Hz, 1H), 7.314 (m, J=8.1Hz, 1H), 7.023 (m, 2H), 6.926 (m, 1H),4.117(m,1H),3.502(m,1H),3.269(m,1H),3.041(m,1H),2.736(m,4H),2.030(m,2H), 1.542(m,4H),1.260(m,2H),0.981(m,3H),0.590(m,3H)。
The activity of resisting tumor metastasis of the measurement of embodiment 24 compound 6a-d
Lewis murine lung cancer cell (LLC the is purchased from ATCC) inoculation of this rating model, selects DMEM culture medium (to contain 10% Fetal calf serum through inactivating, 1 × 105U/L penicillin and 100mg/L streptomysin), it was passed according to attached cell cultural method every two days In generation, is primary, enrichment of cell.Vitellophag when cell growth state is good and is in logarithmic growth phase, is adjusted thin with physiological saline Born of the same parents' density is to 1 × 107A/mL.The dyeing of placenta indigo plant, makes viable count>95%.Take inbred strais C57BL/6 male mice (SPF Grade, 20 ± 2g of weight), the fixed mouse of left hand.It is sterilized with 75% Mice Hepatocytes Injured by Ethanol right fore skin of axillary fossa.It is sterile that the right hand holds 1mL LLC tumor cell suspension is subcutaneously injected toward mouse armpit in syringe, and every mouse injects 0.2mL.After mouse inoculation 10 days, grow The tumour of diameter about 4-5mm is knurl source.The Lewis lung cancer tumor-bearing mice etherization of inoculation 10 days, cervical dislocation are put to death.With 75% ethyl alcohol impregnates 10min, and knurl is removed in disinfection on superclean bench.Select well-grown tumor tissues sterile flat It shreds, is placed in the tissue homogenizer of glass manufacture in ware.The ratio for being again 1 to 3 (g ratio mL) than physiological saline volume in tumor mass The physiological saline that heating degree is 4 DEG C, is lightly ground and cell suspension is made.Cell suspension crosses 200 mesh cell sieve single cell suspensions. With the cell density of physiological saline tune single cell suspension to 1.5 × 107A/mL.The dyeing of placenta indigo plant, makes viable count>95%. Left hand fixes inbred strais C57BL/6 male mice, is sterilized with 75% Mice Hepatocytes Injured by Ethanol right fore skin of axillary fossa.The right hand holds 1mL Tumor cell suspension, every injection 0.2mL is subcutaneously injected in mouse armpit in asepsis injector.Mouse grows diameter 4- after inoculation 10 days Mice Inoculated is grouped by the tumour of 5mm at random by the gross tumor volume measured.Every group of 12 mouse.The 11st day of inoculated tumour is small (dosage is 20 μm of ol/ to the normal saline solution of mouse or oral generally acknowledged anti tumor translocation peptide Arg-Gly-Asp-Ser (RGDS) Kg/ days) or oral administration of compound 6a-d normal saline solution (dosage be 0.5 μm ol/kg/ days) or oral administration of compound 8 physiology Saline solution (dosage be 5 μm ol/kg/ days) or oral normal saline (dosage is 10mL/kg/ days) give 1 medicine, continuously daily Administration 12 days, measures and records gross tumor volume every three days.The next day measurement knurl product of last time administration, etherization take off neck Vertebra is put to death, and the tumour of mouse is taken to weigh, and is taken the lung of mouse and is calculated the burrknot number of tumour lung transfer.With t examine to data into Row statistical analysis.It the results are shown in Table 1.Neoplasm lung metastasis is not only effectively inhibited in 0.5 μm of ol/kg dosages for Compound 6a-d, and And activity does not have significant difference with their high 40 times RGDS of dose ratio and their high 10 times compounds 8 of dose ratio.These Statistics indicate that the present invention has significant technical effect.
The activity of resisting tumor metastasis of 1 compound 6a-d of table
A) with physiological saline ratio p<0.01；B) with physiological saline ratio p<0.01, compare p with RGDS compound 8>0.05；N=11
Embodiment 25 measures the neoplasm growth activity of compound 6a-d
Adriamycin, compound 8 and compound 6a-d are used into physiological saline solution before measurement, are administered for S180 mouse. It is taken in gnotobasis and is inoculated in male ICR mouse 10 days eugonic S180 ascitic tumor fluids, with normal saline dilution at (1: 2) liquid is sufficiently mixed, and by 0.2% Trypan Blue of tumor cell suspension Fresh, white blood cell count(WBC) is pressed after mixing Method counts, and dye blue person is dead cell, and tinter is not living cells.By viable count/4 in cell concentration=4 block plaids × 104× extension rate=cell number/mL calculates cell density, by cell survival rate=viable count/(viable count+dead cell Number) × 100% calculating cell survival rate.It is 2.0 × 10 that density, which is made, with homogenate method in tumor liquid by survival rate greater than 90%7A/ The cell suspension of mL.The cell suspension inoculation is subcutaneous (0.2mL/ is only) in mouse right axillary, manufactures S180 tumor-bearing mice.Inoculation is for 24 hours The normal saline solution (dosage is 2 μm of ol/kg/ days g) or daily oral of adriamycin is injected intraperitoneally in S180 tumor-bearing mice daily afterwards The normal saline solution (dosage be 5 μm ol/kg/ days) of compound 8 or the daily normal saline solution (agent of oral administration of compound 6a-d Amount for 0.5 μm ol/kg/ days).It is administered once a day, successive administration 12 days.The next day measurement knurl product of last time administration, second Ehterization cervical dislocation is put to death, and is then fixed mouse right axillary tumor location with tweezers, is cut off skin blunt separation tumour and claim Weight.Curative effect is indicated with knurl weight (mean value ± SD g), and data are examined with t and variance analysis.It the results are shown in Table 2.In 0.5 μm of ol/kg agent It measures lower compound 6a-d and not only effectively inhibits tumour growth, but also their high 10 times compounds 8 do not have activity with dose ratio Significant difference these statistics indicate that, the present invention has significant technical effect.
Influence of the 2 compound 6a-d of table to S180 mice tumors grew
A) with physiological saline ratio p<0.01, compare p with compound 8<0.05；N=12.
The anti-inflammatory activity of the measurement of embodiment 26 compound 6a-d
Because mouse ear swelling caused by dimethylbenzene is acknowledged as acute inflammation model, the present invention causes in dimethylbenzene Mouse ear swelling model on measure compound 6b-d therapeutic effect.Because aspirin is the positive for treating acute inflammation Medicine, so the present invention selects aspirin for positive control drug.The ring that ICR male mice (20 ± 2g of weight) is 22 DEG C in temperature Border tranquillization 2 days, free water and feed.Later, physiological saline group (dosage is 0.2mL/), aspirin group are randomly divided into (dosage 1.11mmol/kg), (dosage is 0.5 μm of ol/ for 8 groups of compound (dosage is 5 μm of ol/kg) and compound 6a-d group Kg), every group of 12 mouse.Mouse is by place group or oral normal saline or oral aspirin or oral administration of compound when measurement 8 or oral administration of compound 6a-d.After 30min is administered, the left auricle toward mouse uniformly smears 30 μ L dimethylbenzene, and mouse receives after 2h Etherization, the neck that breaks are put to death, and are cut two ears of left and right, are taken round auricle in the same position of two ears with the punch of 7mm, weigh, Two ear swelling differences are found out as swelling.That is swelling=left ear disk weight-auris dextra disk weight.It the results are shown in Table 3.? 0.5 μm of ol/kg dosages for Compound 6a-d not only effectively inhibits mouse ear swelling caused by dimethylbenzene, but also activity and dosage There is no significant difference than their high 10 times compounds 8.These statistics indicate that, the present invention has significant technical effect.
The influence of mouse ear swelling caused by 3 compound 6a-d paraxylene of table
A) with physiological saline ratio p<0.01, compare p with compound 8>0.05；N=12.

Claims (5)

1. (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine -2,5- two of following formula Ketone,
AA is L-Ala residue, Gly residue, L-Met residue and L-IIe residue in formula.
Claim 2. (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine -2,5- The preparation method of diketone, this method include：
(1) D-Boc-Lys (Cbz) and D-Trp-OBzl are condensed to obtain D-Boc-Lys (Cbz)-D-Trp-OBzl；
(2) D-Boc-Lys (Cbz)-D-Trp-OBzl de- Boc in the ethyl acetate solution of hydrogen chloride obtains D-Lys (Cbz)-D- Trp-OBzl；
(3) D-Lys (Cbz)-D-Trp-OBzl containing 5% sodium bicarbonate aqueous solution saturation ethyl acetate middle ring symphysis at (3R, 6R) -3- (benzyloxycarbonyl amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (1)；
(4) the de- benzyloxycarbonyl group of 1 hydrogenolysis of compound obtains (3R, 6R) -3- (amino normal-butyl) -6- (indoles -3- methyl)-piperazine - 2,5- diketone (2)；
(5) Amino-n-hexanoic acid methyl esters and Boc-AA (AA is Ala residue, Gly residue, Met residue and IIe residue in formula) are condensed R-AA- Amino-n-hexanoic acid methyl esters (3a-d)；
(6) compound 3a-c saponification removing methyl esters obtains Boc-AA- Amino-n-hexanoic acid (4a-d)；
(7) compound 2 and compound 4a-d are condensed (3R, 6R) -3- (the positive caproyl amino normal-butyl of Boc-AA- amino) -6- (indoles -3- methyl)-piperazine-2,5-dione (5a-d)；
(8) compound 5a-d de- Boc in the ethyl acetate solution of hydrogen chloride obtains (3R, 6R) -3- (positive caproyl of AA- amino Amino normal-butyl) -6- (indoles -3- methyl)-piperazine-2,5-dione (6a-d).
3. (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine-of claim 1 2,5- diketone is preparing the application in medicine for anti transfer of tumor.
4. (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine-of claim 1 2,5- diketone application in preparation of anti-tumor drugs.
5. (3R, 6R) -3- (the positive caproyl amino normal-butyl of AA- amino) -6- (indoles -3- methyl)-piperazine-of claim 1 The application in preparing anti-inflammatory drugs of 2,5- diketone.
CN201710364632.XA 2017-05-22 2017-05-22 3R-indolylmethyl-6R-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof Expired - Fee Related CN108929313B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710364632.XA CN108929313B (en) 2017-05-22 2017-05-22 3R-indolylmethyl-6R-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710364632.XA CN108929313B (en) 2017-05-22 2017-05-22 3R-indolylmethyl-6R-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof

Publications (2)

Publication Number Publication Date
CN108929313A true CN108929313A (en) 2018-12-04
CN108929313B CN108929313B (en) 2021-06-08

Family

ID=64450838

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710364632.XA Expired - Fee Related CN108929313B (en) 2017-05-22 2017-05-22 3R-indolylmethyl-6R-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof

Country Status (1)

Country Link
CN (1) CN108929313B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503833A (en) * 2014-10-20 2016-04-20 首都医科大学 Indole piperazine dione compound, and preparation and treatment effect thereof
CN106349148A (en) * 2015-07-13 2017-01-25 首都医科大学 Novel indoles compound having anti-tumor metastasis activity and anti-inflammatory activity, as well as synthesis and application of novel indoles compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503833A (en) * 2014-10-20 2016-04-20 首都医科大学 Indole piperazine dione compound, and preparation and treatment effect thereof
CN106349148A (en) * 2015-07-13 2017-01-25 首都医科大学 Novel indoles compound having anti-tumor metastasis activity and anti-inflammatory activity, as well as synthesis and application of novel indoles compound

Also Published As

Publication number Publication date
CN108929313B (en) 2021-06-08

Similar Documents

Publication Publication Date Title
CN109111501A (en) The indoles alcohol derivative of fatty acid/amino acid modification, synthesis, activity and application
CN109081801A (en) The indoles alcohol derivative of acidic amino acid modification, synthesis, activity and application
CN109081803A (en) The indoles alcohol derivative of polar amino acid modification, synthesis, activity and application
CN108976159A (en) The indoles alcohol derivative of ArAA modification, synthesis, activity and application
CN108929320A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- oxazolidone modification, synthesis, activity and application
CN108929313A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- fatty acid/amino acid modification, synthesis, activity and application
CN108976201A (en) Piperazine -2,5- diketone of 3R- indole methyl -6S- ArAA modification, synthesis, activity and application
CN108948137A (en) Piperazine -2,5- diketone of 3S- indolylethyl -6S- polar amino acid modification, synthesis, activity and application
CN109456311A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- ArAA modification, synthesis, activity and application
CN108947978A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R-Tyr modification, synthesis, activity and application
CN108947977A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- amide side chains amino acid modification, synthesis, activity and application
CN108947979A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- polar amino acid modification, synthesis, activity and application
CN108929369A (en) Piperazine -2,5- diketone of 3R- indole methyl -6R- acidic amino acid modification, synthesis, activity and application
CN108976210A (en) Piperazine -2,5- diketone of 3S- indole methyl -6R- ArAA modification, synthesis, activity and application
CN108976211A (en) Piperazine -2,5- diketone of 3S- indole methyl -6R- fatty acid/amino acid modification, synthesis, activity and application
CN108947976A (en) Piperazine -2,5- diketone of 3S- indolylethyl -6S- ArAA modification, synthesis, activity and application
CN108948141A (en) Piperazine -2,5- diketone of 3R- indole methyl -6S-Pro modification, synthesis, activity and application
CN108976208A (en) Piperazine -2,5- diketone of 3S- indole methyl -6R-Met modification, synthesis, activity and application
CN108947975A (en) Piperazine -2,5- diketone of 3S- indolylethyl -6S- fatty acid/amino acid modification, synthesis, activity and application
CN108976277A (en) Piperazine -2,5- diketone of 3R- indole methyl -6S- polar amino acid modification, synthesis, activity and application
CN108976204A (en) Piperazine -2,5- diketone of 3S- indole methyl -6R- aspartic acid modification, synthesis, activity and application
CN112300244B (en) 5-fluorouracil modified by theanine alone or together with RGDS, and synthesis, activity and application thereof
CN112300245B (en) RGDS and theanine co-modified 5-fluorouracil, and synthesis, activity and application thereof
CN110577568B (en) Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis, activity and application thereof
CN108976209A (en) Piperazine -2,5- diketone of 3S- indole methyl -6R- heterocyclic amino acid containing N modification, synthesis, activity and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210608